Protara Therapeutics, Inc. (TARA)
Protara Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in New York City, NY, US. The stock last traded at $3.90, down 0.38% on the session, giving a market capitalisation of $218.9M. On trailing twelve-month figures it carries a trailing P/E of -2.86, a net margin of -38897.2%. Its beta of 1.49 implies it has historically moved more than the broad market.
Protara Therapeutics, Inc. is a biotechnology company actively involved in clinical research and development, striving to identify and advance groundbreaking therapies. Their core mission is to tackle significant medical challenges in both oncology and rare disease domains. The company's leading therapeutic candidate, TARA-002, is an investigational cellular therapy currently under evaluation for the treatment of lymphatic malformations. Furthermore, Protara is developing intravenous choline chloride, a potential phospholipid substrate replacement therapy aimed at addressing liver disease associated with intestinal failure. The organization, which was formerly known as ArTara Therapeutics, Inc., underwent a name change to Protara Therapeutics, Inc. in May 2020. Its principal operations are based in New York, New York.
Protara Therapeutics, Inc. is most often compared with the following Healthcare names: